Skip to main content
Apontis Pharma AG logo

Apontis Pharma AG — Investor Relations & Filings

Ticker · APPH ISIN · DE000A3CMGM5 LEI · 894500ETO1J6MR8PDF91 F Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2025-08-20 Board/Management Inform…
Country DE Germany
Listing F APPH

About Apontis Pharma AG

https://apontis-pharma.de/en/

Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.

Recent filings

Filing Released Lang Actions
APONTIS PHARMA: Changes in the management board
Board/Management Information Classification · 100% confidence The document is a corporate news announcement regarding the departure of the CEO of APONTIS PHARMA AG. It explicitly mentions 'Changes in the management board' in the title and body. While it touches upon M&A activity (the merger squeeze-out), the primary purpose of this specific release is to announce personnel changes at the executive level. Therefore, it falls under the 'Board/Management Information' category.
2025-08-20 English
Half-yearly financial statements 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF-YEAR REPORT 2025' and contains comprehensive financial sections including a 'Group Interim Management Report', 'Consolidated Interim Financial Statements' (balance sheet, income statement, cash flow), and 'Condensed Notes'. It covers the period from January 1 to June 30, 2025. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2025
2025-08-19 English
APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated June 13, 2025, disclosing inside information regarding a 'Merger Squeeze-out Cash Compensation Determination at EUR 10.40'. It explicitly mentions the process under the German Transformation Act (UmwG) and Stock Corporation Act (AktG) related to transferring minority shares to the majority shareholder (Zentiva AG) against cash compensation. This action is directly related to a takeover or merger activity. Reviewing the definitions: - 10-K/IR: Not a full annual or interim financial report. - ER/MDA: Not an earnings release or management discussion. - DIV/SHA: Not a standard dividend or share issue announcement, but related to a corporate action. - The core subject is the determination of cash compensation as part of a squeeze-out following a merger/acquisition process. - The definition for M&A Activity (Code: TAR) is: 'Announcements and documents related to merger proposals or takeover bids.' This document details a critical step (cash compensation determination) in a squeeze-out procedure which is the final stage of a merger/takeover. Therefore, the most appropriate classification is M&A Activity (TAR).
2025-06-13 English
APONTIS PHARMA publishes results for the first quarter of 2025 and confirms forecast for 2025
Earnings Release Classification · 100% confidence The document explicitly states it publishes 'results for the first quarter of 2025' and includes key financial highlights (sales, EBITDA, net income) for the 3-month period (3M 2025 vs 3M 2024), along with condensed statements of income and cash flows. This content structure is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it provides the initial summary of results and confirms the annual forecast, it fits the definition of an Earnings Release (ER) which focuses on periodical financial results highlights. Although it contains detailed tables, the primary function appears to be the initial announcement of the quarterly performance, rather than the comprehensive, audited report implied by 'IR'. Furthermore, the document mentions the figures are 'unaudited', which is typical for an ER/MRQ rather than a full annual report (10-K) or a standalone audit report (AR). Given the focus on Q1 results, 'ER' is the most appropriate classification over 'IR' (which is usually a more comprehensive half-year report). Q1 2025
2025-05-15 English
APONTIS PHARMA with significant sales and earnings increase in 2024 financial year squeeze-out and merger planned
Earnings Release Classification · 100% confidence The document is a press release dated March 31, 2025, announcing the financial results for the 2024 financial year, including significant sales and earnings increases. It contains key financial highlights (Sales, EBITDA, Net result) and condensed financial statements (Income Statement, Balance Sheet, Cash Flow Statement) for 2024 compared to 2023. This structure strongly indicates an initial announcement of periodical financial results. Although it contains detailed financial data, the format is that of a news release summarizing the results, rather than the comprehensive, formally filed Annual Report (10-K) or a detailed Interim Report (IR). The presence of key figures and the announcement nature points directly to an Earnings Release (ER). It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Audit Report (AR). FY 2024
2025-03-31 English
Annual financial statements 2024
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2024' and contains a comprehensive table of contents including a letter to shareholders, group management report, consolidated financial statements, and an independent auditor's report. It provides detailed financial performance data for the fiscal year 2024, including sales and EBITDA figures. As it is a full annual report containing substantive financial statements and management analysis, it is classified as a 10-K. FY 2024
2025-03-31 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.